Herceptin Research Today is a free monthly online journal that collates and summarizes the latest research about Herceptin, including details on side-effects, breast cancer, treatment, therapy.

Volume 3 (2006), Issue 8 (August)

1. AQUA and FISH analysis of HER-2/neu expression and amplification in a small cell lung carcinoma tissue microarray.
   Histopathology, 49(2): 161-9. [Abstract] [Full-text]
2. Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption.
   Proc Natl Acad Sci U S A, 103(31): 11719-23. [Abstract] [Full-text]
3. Adjuvant trastuzumab therapy for HER2-overexpressing breast cancer: What we know and what we still need to learn.
   Eur J Cancer, 42(12): 1715-9. [Abstract] [Full-text]
4. ErbB2 receptor tyrosine kinase signaling mediates early demyelination induced by leprosy bacilli.
   Nat Med, 12(8): 961-6. [Abstract] [Full-text]
5. Targeting HER2 Epitopes.
   Semin Oncol, 33(4): 386-91. [Abstract] [Full-text]
6. Modulation of HER2 expression by ferulic acid on human breast cancer MCF7 cells.
   Eur J Clin Invest, 36(8): 588-96. [Abstract] [Full-text]
7. Trastuzumab in combination with heregulin-activated Her-2 (erbB-2) triggers a receptor-enhanced chemosensitivity effect in the absence of Her-2 overexpression.
   J Clin Oncol, 24(23): 3735-46. [Abstract] [Full-text]
8. The combination of letrozole and trastuzumab as first or second-line biological therapy produces durable responses in a subset of HER2 positive and ER positive advanced breast cancers.
   Breast Cancer Res Treat. [Abstract] [Full-text]
9. Cardiac dysfunction associated with trastuzumab.
   Expert Opin Drug Saf, 5(5): 619-29. [Abstract] [Full-text]
10. Antitumor effect of trastuzumab for pancreatic cancer with high HER-2 expression and enhancement of effect by combined therapy with gemcitabine.
    Clin Cancer Res, 12(16): 4925-32. [Abstract] [Full-text]
11. Trastuzumab (Herceptin)-associated lung injury.
    Respirology, 11(5): 655-8. [Abstract] [Full-text]
12. Simultaneous determination of protein aggregation, degradation, and absolute molecular weight by size exclusion chromatography-multiangle laser light scattering.
    Anal Biochem, 356(1): 76-85. [Abstract] [Full-text]
13. Antibody therapy for early-stage breast cancer: trastuzumab adjuvant and neoadjuvant trials.
    Expert Opin Biol Ther, 6(9): 951-62. [Abstract] [Full-text]
14. Use of trastuzumab for the treatment of early stage breast cancer.
    Expert Rev Anticancer Ther, 6(8): 1153-64. [Abstract] [Full-text]
15. Immunomodulatory oligonucleotides as novel therapy for breast cancer: pharmacokinetics, in vitro and in vivo anticancer activity, and potentiation of antibody therapy.
    Mol Cancer Ther, 5(8): 2106-14. [Abstract] [Full-text]
16. HER-2 gene amplification in paget disease of the nipple and extramammary site: a chromogenic in situ hybridization study.
    Diagn Mol Pathol, 15(3): 131-5. [Abstract] [Full-text]
17. Application and potential limitations of animal models utilized in the development of trastuzumab (Herceptin(R)): A case study.
    Adv Drug Deliv Rev, 58(5): 723-34. [Abstract] [Full-text]
18. Her-2/neu amplification is an independent prognostic factor in gastric cancer.
    Dig Dis Sci, 51(8): 1371-9. [Abstract] [Full-text]
19. Identification of potentially useful combinations of epidermal growth factor receptor tyrosine kinase antagonists with conventional cytotoxic agents using median effect analysis.
    Anticancer Drugs, 17(8): 921-928. [Abstract] [Full-text]
20. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
    J Clin Oncol, 24(25): 4107-15. [Abstract] [Full-text]

© 2004-2008 Herceptin Research Today. All Rights Reserved.